Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

416
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
416
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

1.9K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

337
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
337
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

366
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
366
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

366
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
366

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Stroke and its consequences: protocol and pilot data of the observational Berlin Long-term Observation of Vascular Events (BeLOVE) stroke stratum.

BMJ neurology open·2026
Same author

Local and systemic cytokine signatures for outcome prediction after transarterial chemoembolization in hepatocellular carcinoma.

Theranostics·2026
Same author

Indole-3 Acetate Limits Dysbiosis-Driven Diastolic Failure via Hcrt Neurons.

Circulation research·2026
Same author

Cell Painting Protocol to Characterize Morphological Profiles of Large Compound Collections Using the EU-OPENSCREEN Library.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Deep phenotyping of heart failure with preserved ejection fraction through multi-omics integration.

European journal of heart failure·2025
Same author

Sex-specific changes in energy demand during the preplaque stage in a transgenic Alzheimer's mouse model.

Biology of sex differences·2025

Video Experimental Relacionado

Updated: Dec 18, 2025

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

22.9K

La fosfodiesterasa 3A y la hipertensión arterial

Maria Ercu1,2, Lajos Markó2,3,4, Carolin Schächterle1,2,4

  • 1Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.).

Circulation
|June 12, 2020
PubMed
Resumen

Una nueva mutación en el gen PDE3A causa hipertensión con braquidactilia. Este descubrimiento proporciona nuevos modelos animales y objetivos potenciales para el desarrollo de tratamientos antihipertensivos.

Palabras clave:
Presión arterialgenéticahipertensiónLas fosfodiesterasas

Más Videos Relacionados

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.4K
Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

439

Videos de Experimentos Relacionados

Last Updated: Dec 18, 2025

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

22.9K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.4K
Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

439

Área de la Ciencia:

  • Investigación cardiovascular
  • La genética
  • Biología molecular

Sus antecedentes:

  • La presión arterial alta (hipertensión) es una de las principales causas mundiales de muerte cardiovascular.
  • La hipertensión autosómica dominante con braquidactilia es una forma grave de hipertensión relacionada con la muerte prematura por accidente cerebrovascular.
  • Investigaciones previas implicaron el gen de la fosfodiesterasa 3A (PDE3A), pero faltaban pruebas in vivo.

Objetivo del estudio:

  • Para investigar la base genética de la hipertensión con braquidactilia.
  • Crear y analizar modelos in vivo del defecto genético identificado.
  • Explorar los mecanismos moleculares subyacentes a la hipertensión asociada a la PDE3A.

Principales métodos:

  • Mapeo y secuenciación genética para identificar mutaciones.
  • Edición del gen CRISPR-Cas9 para crear modelos animales (ratas y ratones).
  • Tecnología transgénica, inmunoblotación y estudios de interacción con proteínas para analizar la función de la PDE3A.

Principales resultados:

  • Se identificó un nuevo punto de mutación en el gen PDE3A en pacientes con hipertensión con braquidactilia.
  • Los modelos de ratas y ratones transgénicos generados por CRISPR-Cas9 recapitularon la condición humana.
  • La PDE3A mutada mostró un aumento de la actividad, una alteración de la fosforilación y una mayor interacción con el 14-3-3θ, lo que condujo a la proliferación de células musculares lisas vasculares y a una alteración de la función vascular.

Conclusiones:

  • Las mutaciones en el gen PDE3A causan directamente la hipertensión al aumentar la resistencia vascular periférica.
  • Los modelos animales desarrollados ofrecen herramientas valiosas para una mayor investigación de los mecanismos de la hipertensión.
  • Estos hallazgos pueden allanar el camino para nuevas terapias antihipertensivas dirigidas a la señalización PDE3A.